United States - English - NLM (National Library of Medicine)

biogen inc. - interferon beta-1a (unii: xro4566q4r) (interferon beta-1a - unii:xro4566q4r) - interferon beta-1a 30 ug in 0.5 ml - avonex is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. avonex is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, or any other component of the formulation [see warnings and precautions (5.3)] . the formerly available lyophilized vial formulation of avonex is contraindicated in patients with a history of hypersensitivity to albumin (human). risk summary data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with the use of interferon beta products during early pregnancy. findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta products in pregnancy have been inconsistent (see data). in a study in pregnant monkeys, administration of interfer

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

litha pharma (pty) ltd - injection - see ingredients - each 1 ml solution contains interferon beta 1a 30,0 ug

Canada - English - Health Canada

biogen canada inc - interferon beta-1a - solution - 30mcg - interferon beta-1a 30mcg - immunomodulatory agents

Canada - English - Health Canada

biogen canada inc - interferon beta-1a - powder for solution - 60mcg - interferon beta-1a 60mcg - immunomodulatory agents

Australia - English - Department of Health (Therapeutic Goods Administration)

biogen idec australia pty ltd - interferon beta-1a -

Canada - English - Health Canada

biogen canada inc - interferon beta-1a; water - powder for solution - 30mcg; 1.1ml - interferon beta-1a 30mcg; water 1.1ml - immunomodulatory agents

Israel - English - Ministry of Health

medison pharma ltd - interferon beta 1a 30 mcg/vial - powder for solution for injection - interferon beta-1a - avonex is indicated for the treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. avonex is also indicated for the treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of mri abnormalities characteristic of ms and if they are determined to be at high risk of developing clinically definite multiple sclerosis. safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

wael pharmacy - interferon beta 1 a - solution for injection - 30 mcg/ 0.5 ml

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

pharmaplan (pty) ltd - solution - see ingredients - each pre-filled syringe contains interferon beta 1a 30,0 ug

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

biogen idec b.v-natherland, netherlands - interferon beta-1a - solution for injection - 30 µg